ONCOMED PHARMACEUTICALS INC's ticker is OMED and the CUSIP is 68234X102. A total of 1 filers reported holding ONCOMED PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $0 | – | 380 | 0.0% | 0.00% | – |
| Q4 2018 | $0 | -100.0% | 380 | 0.0% | 0.00% | – |
| Q3 2018 | $1,000 | 0.0% | 380 | 0.0% | 0.00% | -100.0% |
| Q2 2018 | $1,000 | 0.0% | 380 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $1,000 | -50.0% | 380 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $2,000 | 0.0% | 380 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $2,000 | +100.0% | 380 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $1,000 | -66.7% | 380 | 0.0% | 0.00% | -50.0% |
| Q1 2017 | $3,000 | 0.0% | 380 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $3,000 | -25.0% | 380 | 0.0% | 0.00% | -33.3% |
| Q3 2016 | $4,000 | -20.0% | 380 | 0.0% | 0.00% | -25.0% |
| Q2 2016 | $5,000 | +25.0% | 380 | 0.0% | 0.00% | +33.3% |
| Q1 2016 | $4,000 | -55.6% | 380 | 0.0% | 0.00% | -57.1% |
| Q4 2015 | $9,000 | +50.0% | 380 | 0.0% | 0.01% | +40.0% |
| Q3 2015 | $6,000 | -33.3% | 380 | 0.0% | 0.01% | -16.7% |
| Q2 2015 | $9,000 | – | 380 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,108,815 | $4,273,000 | 0.48% |
| Birchview Capital, LP | 372,557 | $387,000 | 0.24% |
| Perceptive Advisors | 1,719,111 | $1,787,000 | 0.05% |
| Fondren Management LP | 25,136 | $26,000 | 0.02% |
| Cannell & Co. | 281,983 | $293,000 | 0.01% |
| APPLETON PARTNERS INC/MA | 66,206 | $69,000 | 0.01% |
| Quinn Opportunity Partners LLC | 66,162 | $69,000 | 0.01% |
| NJ State Employees Deferred Compensation Plan | 38,000 | $40,000 | 0.01% |
| Candriam S.C.A. | 380,000 | $395,000 | 0.01% |
| PRIMECAP MANAGEMENT CO/CA/ | 5,451,400 | $5,669,000 | 0.00% |